|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-6-15
|
|
pubmed:abstractText |
Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an open-labelled, non-randomized dose-escalation phase I study. In all, 12 patients with a history of recurrent superficial bladder cancer were grouped into four dose levels (10-150 mg ml(-1) in 60 ml saline). Six catheter instillations at weekly intervals were used. Cystoscopy and biopsy were performed before and 3 months after the start of treatment. Suramin was assayed using high-performance liquid chromatography, vascular endothelial growth factor (VEGF) using ELISA (enzyme-linked immunosorbent assay), and urinary protein profile using surface-enhanced laser desorption ionisation mass spectroscopy (SELDI). Minimal systemic absorption of Suramin was found at the highest dose of 150 mg ml(-1). Urinary VEGF was affected by Suramin at doses above 50 mg ml(-1), corresponding to the estimated threshold of saturation of Suramin binding to urine albumin. SELDI showed a specific disappearance of urinary protein peaks during treatment. Intravesical Suramin shows lack of toxicity and low systemic absorption. The results of this phase I trial support expanded clinical trials of efficacy at a dose of 100 mg ml(-1) intravesically.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-10022687,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-11207054,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-12478189,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-12569571,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-1380282,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-14583499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-14665946,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-1512858,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-1655808,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-1719003,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-2170005,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-2380344,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-2842336,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-3496343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-358805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-4077932,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-7530595,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-7817482,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-7882614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-7933214,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-8062193,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-8632538,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-8841939,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-8842494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-8995493,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-9393750,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-9581838,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15928663-9773522
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
pubmed-author:BanksR ERE,
pubmed-author:CranstonDD,
pubmed-author:CrewJJ,
pubmed-author:HarrisA LAL,
pubmed-author:JoelS PSP,
pubmed-author:JonesAA,
pubmed-author:Le MonnierKK,
pubmed-author:OrrJ PJP,
pubmed-author:RobertsI S DIS,
pubmed-author:RogersM AMA,
pubmed-author:StreeterEE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2140-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15928663-Administration, Intravesical,
pubmed-meshheading:15928663-Aged,
pubmed-meshheading:15928663-Aged, 80 and over,
pubmed-meshheading:15928663-Antineoplastic Agents,
pubmed-meshheading:15928663-Carcinoma, Transitional Cell,
pubmed-meshheading:15928663-Dose-Response Relationship, Drug,
pubmed-meshheading:15928663-Female,
pubmed-meshheading:15928663-Humans,
pubmed-meshheading:15928663-Male,
pubmed-meshheading:15928663-Maximum Tolerated Dose,
pubmed-meshheading:15928663-Middle Aged,
pubmed-meshheading:15928663-Neoplasm Recurrence, Local,
pubmed-meshheading:15928663-Proteinuria,
pubmed-meshheading:15928663-Suramin,
pubmed-meshheading:15928663-Treatment Outcome,
pubmed-meshheading:15928663-Urinary Bladder Neoplasms,
pubmed-meshheading:15928663-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
|
|
pubmed:affiliation |
Department of Urology, Churchill Hospital, Oxford, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
